Nyxoah (NYXH) - מכפיל EV/EBITDA

Nyxoah S.A. (NYXH) focuses on independently achieving medical milestones and preparing for US sales, completely ignoring merger and acquisition deals. Expert scientists lead the team, confidently scaling innovations for the fight against apnea to a global level. This price chart featuring the 0.00 metric highlights the business's protection provided by patents and strict FDA oversight.
פילוחים אנליטיים של חברת Nyxoah SA (NYXH)

High debt leverage makes the business vulnerable to market shocks and loan servicing costs. The implementation of ESG standards and the reduction of material intensity for Nyxoah S.A. neurostimulators create an internal reserve for cost optimization. The EV/EBITDA multiple valuation correlates the total enterprise value with its operating profit before taxes, depreciation, and amortization. Analyzing this trend allows an investor to determine the asset's real value and the sustainability of its cash flow.